Mevacor, Ditropan Switch Discussions With FDA Proceeding Well – J&J
This article was originally published in The Tan Sheet
Executive Summary
Discussions between FDA and J&J/Merck over the potential Rx-to-OTC switch of cholesterol-reducing statin Mevacor have been moving in a positive direction, J&J Consumer Pharmaceuticals & Nutritional Products Worldwide Chairman Brian Perkins reported
You may also be interested in...
J&J Increases European Consumer Stake With Merck Buyout
Merck says it will seek new partners for future Rx-to-OTC switch drugs in Europe following Johnson & Johnson's buyout of the company's half of their European consumer health joint venture
J&J Increases European Consumer Stake With Merck Buyout
Merck says it will seek new partners for future Rx-to-OTC switch drugs in Europe following Johnson & Johnson's buyout of the company's half of their European consumer health joint venture
J&J Increases European Consumer Stake With Merck Buyout
Merck says it will seek new partners for future Rx-to-OTC switch drugs in Europe following Johnson & Johnson's buyout of the company's half of their European consumer health joint venture